The 10x authorized share increase and preferred stock authorization give the board unlimited capacity for dilutive financings, warrant exercises, and equity compensation. Monitor for immediate follow-on offerings or warrant inducement transactions that could accelerate dilution. The cross-filing DEFA14A (filed 27d ago) flagged these proposals as massively dilutive for a $3M market cap company — this filing confirms those proposals passed.
Price Chart
Executive Summary
Aethlon Medical held its 2026 Annual Meeting on October 1, 2026, with stockholders approving all 10 proposals, including a 10x increase in authorized common shares (20M to 200M), authorization of 20M preferred shares, and approval of warrant exercises and future dilutive financings. The 2020 Equity Incentive Plan was also amended to add 100,000 shares for issuance. This filing confirms the massive dilution runway previewed in the prior DEFA14A proxy materials.
Key Facts
- Stockholders approved increasing authorized common shares from 20,000,000 to 200,000,000 (370,879 for, 27,208 against).
- Stockholders authorized 20,000,000 shares of preferred stock with terms to be set by the Board.
- Stockholders approved issuance of up to 1,126,602 shares upon exercise of warrants from the July 2026 offering.
- The 2020 Equity Incentive Plan was amended to add 100,000 shares for issuance (total share reserve now 319,425).
- All five director nominees were re-elected; Haskell & White LLP was ratified as auditor.
- Only 711,136 shares were outstanding as of the record date; the authorized share increase to 200M represents ~281x the current float.
- Proposal 10 (adjournment) was approved but not used.
Financial Impact
Massive potential dilution: authorized common shares increased from 20M to 200M (10x increase vs 711,136 shares outstanding). Preferred stock authorization of 20M shares adds further dilution overhang. No current market cap is approximately $3M based on 711K shares; 200M authorized shares represent ~281x current float.
Risk Factors
- Extreme dilution risk from 200M authorized shares vs 711K outstanding shares — potential for massive dilution if shares are issued
- Preferred stock authorization allows board to issue shares with terms that could further dilute common holders
- Warrant exercise approval (1.126M shares from July 2026 offering now authorized for Nasdaq Rule 5635(d) purposes
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001683168-26-007542 |
| Document: aethlon_8k.htm | 0001683168-26-007542 |
| Document: 0001683168-26-007542-index-headers.html | 0001683168-26-007542 |
| Document: 0001683168-26-007542-index.html | 0001683168-26-007542 |
| Document: 0001683168-26-007542.txt | 0001683168-26-007542 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | SC 13G | $5.05 $5.07 | ▲ +0.40% | ▼ −0.06% | $5.07 (+0.40%) |
Oct 1, 2026 25d ago | 8-K | $6.45 $6.05 | ▲ +6.20% | ▲ +7.36% | $5.07 (+21.40%) |
Sep 17, 2026 5w ago | 425 | $6.78 $6.77 | ▼ −0.15% | ▼ −0.75% | $5.07 (−25.22%) |
Sep 17, 2026 5w ago | 8-K | $6.78 $6.77 | ▼ −0.15% | ▼ −0.75% | $5.07 (−25.22%) |
Sep 15, 2026 6w ago | 8-K | $1.47 $6.31 | ▲ +329.25% | ▲ +328.43% | $5.07 (+244.90%) |
Sep 4, 2026 7w ago | DEFA14A | $1.81 $1.47 | ▲ +18.78% | ▲ +17.67% | $5.07 (−180.11%) |
Aug 31, 2026 8w ago | 8-K | $2.06 $1.81 | ▼ −12.14% | ▼ −11.99% | $5.07 (+146.12%) |
Aug 13, 2026 10w ago | Press Release | $2.83 $2.73 | ▼ −3.53% | ▼ −2.17% | $5.07 (+79.15%) |
Jul 31, 2026 12w ago | 8-K | $0.6628 $0.6300 | ▲ +4.95% | ▲ +8.46% | $5.07 (−664.94%) |
Jul 7, 2026 16w ago | EFFECT | $0.7297 $0.6850 | ▲ +6.13% | ▲ +6.68% | $5.07 (−594.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers